Core Viewpoint - Wanfu Biology (300482) has received medical device registration certificates from the National Medical Products Administration for its products, indicating a significant advancement in its product offerings and regulatory compliance [1] Group 1 - The company announced the receipt of medical device registration certificates on December 25 [1] - The registered products include a fully automated nucleic acid purification and real-time fluorescence PCR analysis system [1] - Additionally, the company received approval for a nucleic acid testing kit for adenovirus, mycoplasma pneumonia, and parainfluenza virus using fluorescence PCR method [1]

Group 1 - The company Wanfu Bio announced on December 25 that its fully automated nucleic acid purification and real-time fluorescence PCR analysis system has received a medical device registration certificate from the National Medical Products Administration [1] - Additionally, the adenovirus/pneumonia mycoplasma/parainfluenza virus nucleic acid detection kit (fluorescence PCR method) has also been granted the same medical device registration certificate [1]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-076 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于取得产品注册证的公告 广州万孚生物技术股份有限公司（以下简称"万孚生物"或"公司"）近日 收到国家药品监督管理局颁发的医疗器械注册证，具体信息如下： | 名称 | | 注册证号 | | 适用范围 | 有效期至 | | | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 本产品基于磁珠法核酸提取技术和实时荧光 PCR 检测原理，与配套的检测试剂共同使用，自动完 | | 全自动核酸提纯及 | | 国 械 注 准 | | | | 成从核酸提取纯化到扩增、检测一系列操作步 | | 实时荧光 PCR | 分析系 | 20253222465 | | | 2030/11/30 | 骤，在临床上对来源于人体样本中的靶核酸 | | 统 | | | | | | (DNA/RNA)进行定性/定量检测，包括病原体、人 | | | | | | | | 类 ...

Core Viewpoint - The fentanyl concept sector experienced a decline of 0.26% as of the market close on December 24, with several companies within the sector showing significant drops in stock prices [1] Market Performance - The top-performing concept sectors today included: - Terahertz: +4.02% - Commercial Aerospace: +3.60% - Satellite Navigation: +3.47% - Fentanyl: -0.26% [1] Fund Flow Analysis - The fentanyl concept sector saw a net outflow of 63 million yuan from main funds today, with six stocks experiencing significant outflows. The stock with the highest outflow was ST Renfu, which had a net outflow of 42.89 million yuan [1] - Other notable outflows included: - Enhua Pharmaceutical: -13.02 million yuan - Wanfu Biology: -5.15 million yuan - Botao Biology: -2.70 million yuan [1] - Conversely, the stocks with the highest net inflows included: - Guoyao Modern: +1.77 million yuan - Guoyao Shares: +1.47 million yuan [1] Individual Stock Performance - The following stocks within the fentanyl concept sector had notable price changes: - ST Renfu: -2.06% with a turnover rate of 1.92% - Enhua Pharmaceutical: -0.79% with a turnover rate of 0.68% - Wanfu Biology: +0.61% with a turnover rate of 0.51% - Botao Biology: -0.28% with a turnover rate of 0.74% - Guoyao Modern: +0.20% with a turnover rate of 0.51% [1]

Core Insights - The article discusses the registration and quality management system assessments for medical devices in Guangdong Province, highlighting various companies and their products that have undergone evaluations and received approvals or required modifications [2][5]. Group 1: Company Registrations - Guangdong Weinuodun Medical Technology Co., Ltd. received approval for its medical ozone therapy device on November 3, 2025 [3]. - Guangdong Baisheng Medical Instrument Co., Ltd. passed the evaluation for high-frequency surgical equipment on November 3, 2025 [3]. - Shenzhen Kefu Biotechnology Co., Ltd. was approved for its continuous glucose monitoring system on November 4, 2025 [3]. - Guangzhou Wanfu Biological Technology Co., Ltd. received approval for its hepatitis B virus nucleic acid testing kit on November 10, 2025 [3]. - Shenzhen Karman Medical Equipment Co., Ltd. was approved for its intracranial pressure sensor and cerebrospinal fluid drainage set on November 12, 2025 [3]. Group 2: Quality Management System Assessments - The Guangdong Provincial Drug Administration is implementing a quality management system assessment for Class II medical devices, with results communicated to applicants via SMS or web queries since May 2022 [5]. - Companies such as Shenzhen Aibo Hechuang Medical Robot Co., Ltd. received approval for their vascular intervention surgery control system on November 27, 2025 [5]. - Guangdong Tiancheng Tianmei Medical Technology Co., Ltd. was approved for absorbable surgical sutures on November 19, 2025 [4].

Core Viewpoint - The company, Wanfu Biotech, is actively tracking national fertility support policies and adapting its product offerings in the reproductive health sector to align with market demands and policy changes [2][4][5]. Group 1: Company Performance and Market Strategy - As of December 22, 2025, Wanfu Biotech's stock closed at 19.88 yuan, down 0.95%, with a turnover rate of 0.85% and a trading volume of 36,500 shares, amounting to 72.81 million yuan [1]. - The company has seen rapid growth in sales of its glycosylated hemoglobin testing products, driven by new public health policies that include free testing for seniors [3]. - Wanfu Biotech is focusing on expanding its product line in the reproductive health sector, including prenatal infectious disease monitoring and reproductive ability testing, to meet the increasing demand from fertility support policies [2][4][5]. Group 2: Product Development and R&D Investment - The company is committed to increasing R&D investment in its reproductive health segment, particularly in differentiated products like AI-assisted pregnancy tools and sperm quality testing [2][4]. - Wanfu Biotech is exploring collaborations with reproductive centers and maternal and child platforms to enhance market share and promote its products in response to fertility subsidy policies [2][4][5]. - The company is also evaluating the feasibility of developing high-end detection technologies, such as molecular imprinting sensors, in the cannabis testing sector [7]. Group 3: Regulatory and Policy Adaptation - Wanfu Biotech is closely monitoring the implementation of national fertility policies and adjusting its marketing and supply strategies accordingly [2][4][5]. - The company is working on optimizing product pricing and promotional strategies to align with insurance reimbursement scenarios, particularly in the reproductive health testing segment [6][9]. - The company has established a stable supply chain system to mitigate risks associated with raw material price fluctuations and ensure cost control [12].

Group 1 - The company, Wanfu Biology (300482), is actively focusing on its core business and investment opportunities [1]

Core Viewpoint - Wanfu Bio is actively monitoring policy dynamics in the healthcare sector and is focused on product development and scenario adaptation based on clinical and public health needs [1] Group 1: Product Development - The company has a rich product line in the field of reproductive health, including prenatal infectious disease monitoring and fertility testing, which can cover the majority of reproductive health needs [1] Group 2: Market Strategy - Wanfu Bio will dynamically adjust its promotion and supply strategies according to market demand [1]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-076 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于万孚转债预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300482 证券简称：万孚生物 债券代码：123064 债券简称：万孚转债 转股价格：人民币 27.00 元/股 转股时间：2021 年 3 月 8 日至 2026 年 8 月 31 日 根据《广州万孚生物技术股份有限公司向不特定对象发行可转换公司债券募 集说明书》（以下简称"《募集说明书》"）中相关约定：在本次发行的可转换公司 债券存续期间，当公司股票在任意连续三十个交易日中至少有十五个交易日的收 盘价低于当期转股价格的 80%时，公司董事会有权提出转股价格向下修正方案并 提交公司股东大会表决。上述方案须经出席会议的股东所持表决权的三分之二以 上通过方可实施。 广州万孚生物技术股份有限公司（以下简称"公司"）股票自 20 ...

Core Viewpoint - Wanfu Biology (300482.SZ) is actively monitoring policy developments in the healthcare sector and is focused on product development and scenario adaptation based on clinical and public health needs [1] Group 1: Product Development - The company has a comprehensive product line in the field of reproductive health, including prenatal infectious disease monitoring and fertility testing, which can meet the majority of reproductive health needs [1] - Wanfu Biology will dynamically adjust its promotion and supply strategies according to market demand [1]